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Abstract 
In 2010, the Purdue University College of Pharmacy established the Medication Safety Research Network of Indiana (Rx-SafeNet), the 
first practice-based research network (PBRN) in Indiana comprised solely of community pharmacies.  In the development of Rx-
SafeNet and through our early project experiences, we identified several “lessons learned.”  We share our story and what we learned 
in an effort to further advance the work of the greater PBRN community.  We have formed the infrastructure for Rx-SafeNet, 
including an Executive Committee, Advisory Board, member pharmacies/site coordinators, and Project Review Team.  To date, 22 
community pharmacies have joined and we have recently completed data collection for the network’s first project.  Lessons learned 
during the development of Rx-SafeNet may benefit PBRNs nationally.  Although community pharmacy PBRNs are not yet 
commonplace in the U.S., we believe their development and subsequent research efforts serve as an important avenue for 
investigating medication use issues. 
 
 
Introduction 
In 2010, the Purdue University College of Pharmacy 
established the Medication Safety Research Network of 
Indiana (Rx-SafeNet), which is administered by the College’s 
Center for Medication Safety Advancement (CMSA).
1
  Rx-
SafeNet is the first practice-based research network (PBRN) in 
Indiana comprised solely of community pharmacies.
2
  To our 
knowledge, Rx-SafeNet is also one of only a very few PBRNs 
nationally to focus on community pharmacy practice,
3-5
 and 
the only to focus specifically on medication safety.   
 
Community pharmacy PBRNs, like Rx-SafeNet, offer
 
unique 
benefits and research opportunities beyond those of 
traditional primary care PBRNs. These benefits have been 
previously described extensively and include: community 
pharmacists’ access to and frequent contact with patients, 
unique involvement in the medication use process, and ability 
to observe self-care behaviors involving over-the-counter  
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medications and supplements provide community pharmacy 
PBRNs with opportunities for insight into medication use 
issues from another perspective.
6
  
 
The launch of Rx-SafeNet is one of several initiatives on which 
the College is collaborating with the goal of advancing new 
community pharmacy practice models that improve 
medication safety in Indiana.  Related efforts include 
collaboration with community pharmacies to provide 
community pharmacy residency/fellowship training and with 
our state pharmacy association to form a pharmacist practice 
network to support pharmacist provision of medication 
therapy management, collaborative drug therapy 
management,  and other patient care services to community-
based patients.  Start-up financial support for these efforts 
was provided by a Lilly Endowment, Inc. grant received by the 
College in 2006.  In the development of Rx-SafeNet and 
through our early project experiences, we identified several 
“lessons learned.”  In this paper, we share our story and what 
we learned in an effort to further advance the work of the 
greater PBRN community, particularly pharmacy PBRNs.  We 
have emphasized specific issues that do not appear to have 
been discussed extensively in previous PBRN literature. 
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Summary of Steps Taken in Network Development 
A timeline describing our development steps is provided in 
Figure 1.  The decision to establish a community pharmacy 
PBRN was made in the fall of 2009.  This decision was reached 
after several early conversations to determine stakeholder 
support.  These included meetings with leaders in the 
pharmacy community, the College of Pharmacy, and the 
University.  Specifically, we first met with the Medication 
Safety Partnership of Indiana, a group representing numerous 
pharmacy organizations in the state interested in medication 
safety, to assess initial interest in a PBRN endeavor and 
answer questions.  Initial support at the College level was 
sought from the Head of the Department of Pharmacy 
Practice and the Managing Director of CMSA.  We also 
reached out to our University Institutional Review Board (IRB) 
early on to begin to discuss the unique human subjects 
protections issues raised by the formation of a PBRN, pulling 
from the experience of other networks (such as human 
subjects protections training requirements for participating 
clinicians, etc.). 
 
During this time, we also began to write our mission 
statement, draft network policies, and form an advisory 
board.  We identified potential advisory board members with 
a variety of professional backgrounds, including practicing 
community pharmacists, pharmacy faculty, individuals with 
PBRN development and administration experience (including 
both pharmacy and other PBRNs), and a medication safety 
expert (CMSA Managing Director) who could help guide the 
mission of the network.  Throughout this process we 
reviewed the PBRN literature and modeled our initial policy 
drafts after others, primarily physician networks (i.e., the 
American Academy of Family Physicians National Research 
Network),
7,8
 as we found, not surprisingly, most information 
available was for primary care PBRNs.  Additionally, we 
surveyed Indiana community pharmacy employees in order 
to gauge overall interest in joining a PBRN, the benefits and 
barriers to joining a network, potential research topics, as 
well as pertinent background and demographic 
information.
9,10
  In total, 140 pharmacists and 40 support staff 
responded to the survey, and in doing so helped the network 
identify key areas in which to focus efforts and resources.  For 
example, the survey identified an overwhelming desire to 
have more information about PBRNs in general, and 
specifically Rx-SafeNet.  This informed a series of outreach 
events (described below), including live information sessions 
held in geographically diverse Indiana cities, as well as the 
development of Rx-SafeNet “FAQs” that were presented 
during the sessions.  Perhaps, more important to the 
longevity of the network, was the fact that the barriers and 
benefits results were interpreted and used to guide the 
development of the policies and procedures of the network, 
allowing for preemptive diminishing and highlighting of the 
issues respectively. 
 
Finalizing network policies included a review by the 
Department Head and also a conversation with the University 
contracting office.  We were required to seek out the latter 
specifically for approval of the Memorandum of 
Understanding that each member pharmacy is asked to sign 
when joining Rx-SafeNet.  The intent of this document was 
not to provide a binding legal contract, but to offer each 
prospective member a set of assurances that all members 
have agreed to abide by the same guidelines and that nothing 
would represent a breach of their standard duties to their 
patients or parent companies (as applicable).  After the 
survey was completed, the network was named and 
registered with the Agency for Healthcare Research and 
Quality PBRN Resource Center as an Affiliate PBRN
11
 and 
initial policies were finalized, we then began to formally 
conduct outreach activities and invite pharmacies to join Rx-
SafeNet.  We engaged in several outreach efforts, including 
contacting pharmacy leaders directly, hosting webinars, 
conducting live information sessions in four locations 
throughout the state, and purchasing exhibit booth space at 
state pharmacy association meetings.  While our state has a 
centrally located capital, which is also our most populous city, 
we found it to be incredibly important to reach out to 
pharmacies in their own communities as a sign of making this 
a true statewide effort.  Continued statewide outreach is 
ongoing. 
 
Resulting Rx-SafeNet Infrastructure 
Rx-SafeNet is led by a three member executive committee 
which consists of the Network Director (full-time Purdue 
Pharmacy Practice tenure-track faculty responsible for 
overseeing the College’s community pharmacy/medication 
safety initiatives), Network Coordinator (0.45 pharmacist FTE 
with the PBRN, remaining effort devoted to the College’s 
other community pharmacy/medication safety efforts), and a 
postdoctoral pharmacist research fellow mentored by the 
Director.  In addition, the executive committee meets 
quarterly with an advisory board.  As described above, 
advisory board members include both pharmacists and non-
pharmacists and several individuals with PBRN experience, 
including those in leadership roles with the Indiana Clinical 
and Translational Sciences Institute (CTSI)
12
 and other local 
networks. 
 
We also formed a Project Review Team (PRT).  The PRT is 
responsible for reviewing submitted project protocols to 
provide guidance not only on scientific issues, but also on 
feasibility and project implementation issues in a community 
pharmacy environment.  The PRT currently consists of Purdue 
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Pharmacy Practice faculty, but the intent is to ultimately 
invite practicing clinicians to participate as well.  The process 
for how projects are selected for completion within Rx-
SafeNet is available on our website 
(http://www.pharmacy.purdue.edu/rx-safenet/). 
 
Current Status 
To date, 22 community pharmacies have joined Rx-SafeNet.  
Data collection for the first project conducted in collaboration 
with the network has been completed. This initial project 
involved only one network pharmacy location as we describe 
further in our lessons learned. At this time, we have received 
project idea submissions from network leadership, other 
colleges in our University, outside technology vendors, and 
community pharmacy residents affiliated with Purdue. 
 
Lessons Learned 
Infrastructure/General Developmental Issues 
1.  Published guidance regarding “essential elements” of 
PBRN infrastructure has worked well for a new non-primary 
care (i.e., community pharmacy) PBRN. 
Green et al. describe infrastructure elements necessary for all 
PBRNs, along with mission-specific elements that will vary.
13
  
Although their paper focuses on primary care PBRNs, we have 
found that their recommendations are applicable to a 
community pharmacy PBRN.  Except for two-way 
communication among members and regular network 
meetings (which are being planned), Rx-SafeNet as a young 
PBRN has developed each of the “common infrastructure 
elements” (including a membership roster, a board, a 
director, a coordinator, a news-sharing function, and a means 
of addressing IRB and HIPAA issues) and to date, they appear 
to be reasonably effective.
13
  Furthermore, we believe the 
recommendations regarding “mission-dependent” elements 
are also very relevant to pharmacy or pharmacist networks.  
Rx-SafeNet emphasizes practice staff (pharmacists, 
technicians, etc.) as active collaborators that may conduct the 
majority of data collection for some studies; therefore, we 
have placed less of an emphasis on using research assistants 
(RAs) to serve this role.  For networks less focused on 
engaging practice staff directly in research activities, RAs may 
play a greater role.  Additionally, Rx-SafeNet has not 
addressed some of the information technology infrastructure 
considerations presented by Green et al.
13
  For example, 
because the same pharmacy management software programs 
are not used across all community pharmacies (i.e., the entire 
potential Rx-SafeNet membership pool of independent 
pharmacies, chains, etc.), common data elements (e.g., drug 
therapy problems detected through the provision of direct 
patient care services) are not always documented and 
therefore, potentially unavailable. 
 
2.  IRB decisions will vary widely across PBRNs; early 
conversations are important. 
As we discussed, we took examples from the PBRN literature 
to initial meetings with our IRB to discuss human subjects 
protections issues.  One of the issues we identified early on 
was a need for a “non-affiliated investigator” mechanism to 
cover Rx-SafeNet clinicians under our University’s 
Federalwide Assurance, as community pharmacies do not 
routinely hold assurances or report to an IRB of their own.  
Although we shared information from Graham et al. who 
describe a non-affiliated investigator agreement (NIA) that 
appears to only be completed by the investigator once every 
three years,
8
 our IRB crafted an agreement that is project-
specific.  Therefore, a new NIA is required by each non-
affiliated investigator for each project they collaborate on 
that details the specific project-related activities that the non-
affiliated investigator will engage in. 
 
3.  “Pre-launch” surveys can assist in ongoing network 
planning and development. 
As mentioned above, a pre-launch survey was executed that 
queried Indiana community pharmacy employees about their 
interests, perceptions of benefits and barriers to joining a 
PBRN, and pertinent background (e.g. previous research 
experience) and demographic (e.g. pharmacy type) 
information.
9,10
  One goal of the survey was to create network 
“ownership” among community pharmacy stakeholders in 
the state by inviting survey respondents to vote on the 
official name of the new PBRN and provide input that 
influenced network policies and procedures.  The survey 
responses also serve as baseline data to which the results of 
future membership surveys can be compared, in order to 
identify long-term trends in interests, concerns and perceived 
value to being an Rx-SafeNet member. 
 
4.  Insight from practicing clinicians could prove enormously 
helpful in refining project protocols. 
As previously described, the PRT currently consists of Purdue 
Pharmacy Practice faculty, but the intent is to invite 
practicing clinicians to participate as well in the future.  
Through the implementation of our first project, the protocol 
was reviewed by the PRT and Rx-SafeNet Executive 
Committee for appropriateness.  However, upon visiting the 
Rx-SafeNet pharmacy to provide staff training on project 
implementation, the site coordinator quickly identified issues 
that required clarification and opportunities to make 
additional improvements.  Having practice staff participating 
in initial PRT review of the proposed protocols will likely help 
to further streamline the process to ensure projects can be 
easily implemented in a community pharmacy setting with as 
few disruptions in workflow as possible.  Despite this, we 
realize that every pharmacy will be unique and may require 
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small changes to work effectively in an individual site’s 
existing workflow. 
 
Membership and Outreach Issues 
1.  In community pharmacy, where a large proportion of the 
market is encompassed by chains, both “top-down” and 
“bottom-up” outreach approaches seem to be warranted. 
As described above, we have utilized several approaches for 
getting the word out about Rx-SafeNet.  These have included 
both “top-down” (e.g., contacting corporate pharmacy 
leadership directly) and “bottom-up” (e.g., inviting all 
community pharmacy employees to attend information 
sessions) approaches.  Although Rx-SafeNet is still in its 
infancy, we believe this approach has value.  The information 
sessions and attendance at state association meetings have 
been helpful in raising individual pharmacist interest and 
awareness.  However, the decision-makers for most (i.e., 
chain) community pharmacies are not at the store level and 
may not be present at these sessions.  Therefore, it has been 
important to identify who in an organization can provide 
approval (i.e., sign the membership MOU) for a pharmacy to 
join the network and to reach out to them to provide more 
information.  Depending on the organization, the individual 
with the authority to give permission to join could be at 
different corporate levels.  This is still ongoing for our 
network and has been one of the greatest challenges Rx-
SafeNet has faced in growing its membership.  Other 
community pharmacy PBRNs have excluded chain pharmacies 
from participation,
3,4
 perhaps partially because of these 
issues, but we continue to pursue engaging chain pharmacies 
as we value representation from a variety of community 
pharmacies. 
 
2.  In defining roles within community pharmacy PBRNs, 
flexibility is key. 
When each pharmacy joins the network, we ask them to 
name a site coordinator.  We realized early on that for some 
pharmacies, particularly those with multiple locations, the 
pharmacy may prefer to name “co-site coordinators” with a 
single individual in a leadership role for the company named, 
along with an individual (e.g., pharmacy manager) at the 
particular pharmacy.  This approach enables pharmacy 
leadership within an organization to “stay in the loop” on all 
network communications and seems to have worked well for 
Rx-SafeNet members choosing to employ this approach.  This 
experience has emphasized for us a need to be flexible in 
adjusting our policies and procedures to reflect the reality of 
community practice. 
 
3.  Balancing the network’s philosophy of ongoing 
collaboration on a variety of projects over time with the 
perception that some practitioners want to focus on a specific 
project is a challenge during initial outreach. 
Recently, network leadership have been advised that 
practitioners would be more likely to join Rx-SafeNet if they 
were interested in a specific project.  While we certainly 
recognize this and are able to share with interested 
practitioners examples of project ideas that have been 
submitted, pursued, or that network leadership are 
interested in, we have also attempted not to emphasize any 
one project.  Our primary concern is creating a confirmation 
bias about the nature of the network or the type of 
involvement that is expected from the membership.  This 
type of bias could lead to two issues: 1) pharmacies refrain 
from joining because they are not interested in early project 
opportunities and do not understand that future projects 
may be quite different, and 2) pharmacies join to participate 
in a specific project without a significant interest in 
participating in future projects.  We continue to assess the 
balance between fostering early excitement for the network 
by offering specific targeted research projects and avoiding a 
confirmation bias that could be detrimental to the future of 
the organization. 
 
Project Development and Implementation Issues 
1.  Starting small has been key in identifying potential project 
implementation issues and refining PBRN procedures. 
We have recently completed data collection for the first small 
study on which the network is collaborating.  Data for this 
study were in the form of questionnaires completed by the 
pharmacist during the course of normal counseling activities 
with a specific patient population. The participating 
pharmacist did not alter their counseling behavior for these 
patients, but made a note of the types of patient questions 
and medication-related problems identified. Data collection 
occurred at one pharmacy, as most of the pharmacies in Rx-
SafeNet signed up after the network was approached with 
this project. We decided to include this as an official network 
project even with only one pharmacy participating as an 
opportunity to test our network processes and policies for 
future projects. While future projects will engage multiple 
pharmacies, we have found that starting very small has been 
extremely helpful in refining our policies and network 
workflow.  For example, this project gave us experience in 
convening the project review team.  In addition, as this 
project was submitted by non-network leadership or 
pharmacy members, it prompted us to develop a guidance 
document for non-member investigators wishing to 
collaborate with the network to ensure everyone is on the 
same page.  Furthermore, we worked to develop a 
standardized approach to the style of training materials and 
data collection training activities and created a system for 
tracking Collaborative Institutional Training Initiative (CITI) 
Idea Paper PRACTICE-BASED RESEARCH 
 
http://z.umn.edu/INNOVATIONS                        2012, Vol. 3, No. 2, Article 78                          INNOVATIONS in pharmacy   5 
 
training completion, which is required of all practitioners 
(depending on their role in the research) participating in 
network projects.  Finally, it has allowed us to reflect on our 
communication practices and training procedures, including 
methods for data transfer, and make adjustments.  Working 
on our initial project with a pharmacy that is truly engaged 
and enthusiastic about this concept has been helpful.  The 
pharmacy is very flexible and full of ideas to improve the 
process. 
 
Discussion 
As evidenced above, the development of Rx-SafeNet was 
primarily modeled after the work of our primary care PBRN 
colleagues and, at least early in the network’s lifecycle, this 
approach has worked well.  In Indiana, this has resulted in the 
first PBRN in our state to focus on community pharmacy, 
which we believe serves as an important complement to the 
other PBRNs that exist, including networks focused on 
primary care, pediatrics, family medicine, oncology, and 
adolescent medicine.
14-18
  Rx-SafeNet leadership have had the 
opportunity to interact with these networks through 
meetings sponsored by the Indiana Clinical and Translational 
Sciences Institute (CTSI).
12
  Although cross-network 
collaborative projects between Rx-SafeNet and the physician 
networks have not yet been pursued, we believe this is an 
excellent opportunity for future collaborative efforts.  We are 
aware of other networks that appear to be considering this 
type of collaboration as well.
19
 Primary care PBRNs with an 
existing connection to colleges of pharmacy through their 
sponsoring university or local Clinical and Translational 
Science Award (CTSA) institution
20
 may benefit from pursuing 
this type of collaboration.  Research exploring the medication 
use process, medication safety concerns, or medication-
taking behaviors may be especially appropriate for cross-
network engagement with primary care PBRNs, as primary 
care physicians are active in the prescribing, administration, 
and monitoring stages and community pharmacists are 
routinely more active in the dispensing and monitoring stages 
which, together, offers a more complete picture of patients’ 
medication use and taking behaviors. 
 
Although we found many similarities among Rx-SafeNet and 
the experiences of other networks, we discovered unique 
challenges and “lessons learned” that we offer up.  As 
mentioned, we believe Rx-SafeNet is unique among existing 
and previous community pharmacy PBRNs for two main 
reasons:  1) Unlike Rx-SafeNet, many of the PBRNs that we 
are aware of are composed of pharmacists (not necessarily 
practicing in community) rather than pharmacies,
4,21,22
 and 2) 
some of the other community pharmacy PBRNs we are aware 
of do not invite chain community pharmacies to participate.
3,4
  
The decision to focus on community pharmacy in Rx-SafeNet 
was made based on an increased overall focus on community 
pharmacy practice within the College of Pharmacy.  Since its 
creation, Rx-SafeNet leadership have been approached by 
physician office or clinic-based pharmacists interested in 
participating, but the decision was made to limit participation 
to community pharmacies because of the need to focus on 
developing and advancing practice in this setting.  Some of 
the workflow and procedural challenges that may make 
research more challenging in the community pharmacy 
setting, including chains, represent the same reasons that a 
focus is needed to help advance practice in these settings. 
 
Rx-SafeNet recognizes the important role of technicians and 
other support staff in community pharmacy practice and the 
impact they could have on implementing projects.  Because 
of this, the network attempts to engage pharmacy 
technicians and other support staff in the research process.  
The pre-launch survey administered to community pharmacy 
employees statewide during the development of Rx-SafeNet 
to assess interest and perceived barriers to participating in a 
PBRN included technicians and other support staff.
9,10
  The 
membership registry survey collecting data on member 
pharmacies upon joining Rx-SafeNet specifically asks for 
information regarding technicians’ education and special 
training. 
 
Conclusions 
Developing a community pharmacy network has provided 
network leadership the opportunity to reflect on many 
“lessons learned” that we believe have not yet been 
extensively described in U.S. PBRN literature.  Although 
community pharmacy PBRNs are not yet commonplace in the 
U.S., we believe their development and subsequent research 
efforts, including those conducted in collaboration with 
primary care PBRNs, serve as an important avenue for 
investigating medication use issues. 
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Figure 1. Rx-SafeNet Development Timeline 
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